Full-Time

Global Applied Statistics & Analytics Head

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Senior, Expert

Remote in USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Machine Learning
Data Analysis

You match the following Legend Biotech's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • B.S. required, Ph.D. preferred in statistics discipline or applied statistics
  • Minimum 12 years of industrial biologics CMC development or manufacturing experience, CAR-T experience is highly desirable.
  • Extensive experience in cell therapy commercial cGMP program with end-to-end know-how to manage process platform changes/improvements in a global manufacturing network and change management process.
  • Candidate must have extensive experience in Cell Therapy tech transfer and/or MSAT.
  • Extensive experience in a cross functional CMC team as a technical statistics and analytics representative supporting global commercial programs in cell therapy
  • Extensive experience employing statistical and analytical methods to solve complex manufacturing issues in cGMP
  • Experience in driving consistent statistical approaches and defending them to health authorities
  • Experience in collaborating with internal technical SMEs to develop pragmatic solutions and deliverables around validation and comparability
  • Industry leading knowledge in technology transfer, process comparability, CMC regulatory guidelines and manufacturing in cell therapy.
  • Ability to think critically and demonstrated troubleshooting and problem-solving skills.
  • Results driven with strong analytical, problem solving and critical thinking skills.
  • Strong experience working in a cross-functional organization with multiple partners with competing priorities.
  • Ability to plan, multitask, prioritize and be an effective and influential decision maker focused on action and implementation.
  • Language: English
Responsibilities
  • Build Statistical Center of Excellence intended to drive global statistical approaches and methods
  • Represent MSAT at joint statistical and analytical committee forums
  • Partner closely with global manufacturing sites to solve complex, inter-dependent, multi-variate/factor technical problems and establish statistical models to correlate all process parameters
  • Provide statistical and analytics mentorship/leadership for an expanding global manufacturing network for best-in-class CAR-T product
  • Provides applicable cell biology or cell therapy related statistics expertise as dedicated support to cell therapy SMEs and the vector programs
  • Develop statistical analyses
  • Provides advanced statistical analyses and development of simulation models (ie. predictive of risks to study failure)
  • Expertise and development of industry leading advanced statistical methods/tools, Machine Learning and AI tools
  • Serves as primary SME for Health Authority interactions, responses to agency questions (RFIs), drafting industry guidelines, support for revisions to specification & critical limits, and training
  • Works closely with the site to gather data and reporting requirements and aligns tools/models/reporting
  • Develops plans to build out end-to-end manufacturing data systems. Scope includes industry leading GxP Part 11 compliant analytical tools and systems from ingestion through reporting
  • Establishes global tiered data governance business processes to align across manufacturing nodes
  • Employs industry leading methodologies and standard approaches specific to cell therapy products (ie. modified Nelson/Shewart rules, Equivalence vs. Expectation approaches for comparability)
  • Drives justification and alignment with key partners (ie. JnJ)
Desired Qualifications
  • CAR-T experience is highly desirable.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their therapies, such as CAR-T, involve modifying a patient's own cells to enhance their ability to fight cancer. Unlike many companies that focus on a single technology, Legend Biotech explores various technologies to find effective treatments. They operate in the personalized medicine sector, discovering, developing, and bringing new therapies to market, generating revenue through licensing and sales. The company emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
  • New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
  • Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

What critics are saying

  • Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
  • Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
  • Financial strain from new R&D facility could affect operational focus if advancements lag.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
  • Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-1%
ROI-NJ
Nov 5th, 2024
Legend Biotech Names Alan Bash As Leader Of Its Cer-T Product

Legend Biotech Corporation on Tuesday said it appointed Alan Bash as president of its CAR-T product CARVYKTI®. In this newly created role, Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing the Somerset-based firm’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” Ying Huang, chief executive officer of Legend Biotech said. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Previously, Bash served as chief executive officer for two oncology-focused biotech companies, most recently at ZielBio, and before that, as president and CEO at Checkmate Pharmaceuticals. He also had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas—including oncology—driving the U.S. launch of Opdivo® and the expansion of additional cancer treatments such as Yervoy® and Erbitux ®.Bash contributed to several blockbuster products in collaboration with other companies, including Abilify® with Otsuka and Eliquis® with Pfizer.“As the fastest launched CAR-T product on the market, CARVYKTI has already produced impressive momentum,” Bash said

GlobeNewswire
Nov 4th, 2024
Legend Biotech Appoints Alan Bash As President Of Carvykti(R)

SOMERSET, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced the appointment of Alan Bash as the Company’s President of CARVYKTI®. In this newly created role, Mr. Bash will be responsible for managing the continued growth of CARVYKTI®, overseeing Legend Biotech’s commercial, technical operations, and quality functions of the franchise.“This expansion in our leadership structure is on the heels of CARVYKTI’s recent successes, including recent approvals from the U.S. Food and Drug Administration and European Commission for label expansion,” said Ying Huang, Ph.D., Chief Executive Officer of Legend Biotech. “Legend Biotech welcomes Alan and is confident that his wealth of operational knowledge in oncology will help further strengthen the Company’s leadership role in the treatment of multiple myeloma.”Mr

BioBuzz
Oct 30th, 2024
Legend Biotech Chooses Philadelphia for New R&D Center

With a global workforce of 1,500 employees, including 350 in R&D, Legend is expanding its manufacturing capabilities with new facilities in New Jersey and beyond.

Global Culture Review
Oct 3rd, 2024
Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

SOMERSET, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) - Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), announced it is establishing a new, state-of-the-art research and development (R&D) facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.

Stock Titan
Sep 24th, 2024
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).